Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.
Identifieur interne : 001392 ( PubMed/Corpus ); précédent : 001391; suivant : 001393Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.
Auteurs : S. Bourgoin ; S. Rostaing-Rigattieri ; J P Nguyen ; E. Berberich ; P. Duvaldestin ; C M Fattaccini ; M. Hamon ; F. CesselinSource :
- Clinical neuropharmacology [ 0362-5664 ]
English descriptors
- KwdEn :
- Adult, Aged, Dopamine (cerebrospinal fluid), Dopamine (metabolism), Electric Stimulation Therapy, Enkephalin, Methionine (cerebrospinal fluid), Female, Humans, Male, Middle Aged, Multiple Sclerosis (cerebrospinal fluid), Multiple Sclerosis (therapy), Parkinson Disease (cerebrospinal fluid), Parkinson Disease (therapy), Serotonin (cerebrospinal fluid), Serotonin (metabolism), Thalamic Nuclei (metabolism).
- MESH :
- chemical , cerebrospinal fluid : Dopamine, Enkephalin, Methionine, Serotonin.
- chemical , metabolism : Dopamine, Serotonin.
- cerebrospinal fluid : Multiple Sclerosis, Parkinson Disease.
- metabolism : Thalamic Nuclei.
- therapy : Multiple Sclerosis, Parkinson Disease.
- Adult, Aged, Electric Stimulation Therapy, Female, Humans, Male, Middle Aged.
Abstract
High-frequency electrical stimulations of thalamic nuclei are currently used for the suppression of parkinsonian or essential tremor and for the relief of some types of intractable pain in man. However, the mechanisms by which such stimulations exert their therapeutic effects are essentially unknown. Attempts were made to provide some insight into these mechanisms by measuring the levels of the dopamine metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) and met-enkephalin-like immunoreactivity in ventricular cerebrospinal fluid (CSF) of patients with Parkinson's disease (PD) or multiple sclerosis (MS) after a 30-minute therapeutic electrical stimulation of the ventralis intermedius nucleus of the thalamus. In nonstimulated control patients, the levels of these compounds did not significantly differ in two CSF samples taken 30 minutes apart. In stimulated patients, a decrease in dopamine metabolite levels associated with a relative increase in met-enkephalin-like immunoreactivity were observed in the CSF sample taken after the 30-minute stimulation as compared to the sample taken immediately before the stimulation. In contrast, the levels of 5-HIAA remained unaffected by the stimulation. These data confirmed the existence of negative interactions between dopaminergic and enkephalinergic systems in man similar to those previously demonstrated in rats. In addition, they suggest that alterations in dopaminergic or enkephalinergic neurotransmission might be involved in the therapeutic action of thalamic electrical stimulation in patients with parkinsonian symptoms and other patients.
PubMed: 10442254
Links to Exploration step
pubmed:10442254Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.</title><author><name sortKey="Bourgoin, S" sort="Bourgoin, S" uniqKey="Bourgoin S" first="S" last="Bourgoin">S. Bourgoin</name><affiliation><nlm:affiliation>INSERM U.288, Faculty of Medicine Pitié-Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rostaing Rigattieri, S" sort="Rostaing Rigattieri, S" uniqKey="Rostaing Rigattieri S" first="S" last="Rostaing-Rigattieri">S. Rostaing-Rigattieri</name></author><author><name sortKey="Nguyen, J P" sort="Nguyen, J P" uniqKey="Nguyen J" first="J P" last="Nguyen">J P Nguyen</name></author><author><name sortKey="Berberich, E" sort="Berberich, E" uniqKey="Berberich E" first="E" last="Berberich">E. Berberich</name></author><author><name sortKey="Duvaldestin, P" sort="Duvaldestin, P" uniqKey="Duvaldestin P" first="P" last="Duvaldestin">P. Duvaldestin</name></author><author><name sortKey="Fattaccini, C M" sort="Fattaccini, C M" uniqKey="Fattaccini C" first="C M" last="Fattaccini">C M Fattaccini</name></author><author><name sortKey="Hamon, M" sort="Hamon, M" uniqKey="Hamon M" first="M" last="Hamon">M. Hamon</name></author><author><name sortKey="Cesselin, F" sort="Cesselin, F" uniqKey="Cesselin F" first="F" last="Cesselin">F. Cesselin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1999 Jul-Aug</MedlineDate></PubDate></date><idno type="RBID">pubmed:10442254</idno><idno type="pmid">10442254</idno><idno type="wicri:Area/PubMed/Corpus">001392</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001392</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.</title><author><name sortKey="Bourgoin, S" sort="Bourgoin, S" uniqKey="Bourgoin S" first="S" last="Bourgoin">S. Bourgoin</name><affiliation><nlm:affiliation>INSERM U.288, Faculty of Medicine Pitié-Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rostaing Rigattieri, S" sort="Rostaing Rigattieri, S" uniqKey="Rostaing Rigattieri S" first="S" last="Rostaing-Rigattieri">S. Rostaing-Rigattieri</name></author><author><name sortKey="Nguyen, J P" sort="Nguyen, J P" uniqKey="Nguyen J" first="J P" last="Nguyen">J P Nguyen</name></author><author><name sortKey="Berberich, E" sort="Berberich, E" uniqKey="Berberich E" first="E" last="Berberich">E. Berberich</name></author><author><name sortKey="Duvaldestin, P" sort="Duvaldestin, P" uniqKey="Duvaldestin P" first="P" last="Duvaldestin">P. Duvaldestin</name></author><author><name sortKey="Fattaccini, C M" sort="Fattaccini, C M" uniqKey="Fattaccini C" first="C M" last="Fattaccini">C M Fattaccini</name></author><author><name sortKey="Hamon, M" sort="Hamon, M" uniqKey="Hamon M" first="M" last="Hamon">M. Hamon</name></author><author><name sortKey="Cesselin, F" sort="Cesselin, F" uniqKey="Cesselin F" first="F" last="Cesselin">F. Cesselin</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dopamine (cerebrospinal fluid)</term><term>Dopamine (metabolism)</term><term>Electric Stimulation Therapy</term><term>Enkephalin, Methionine (cerebrospinal fluid)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multiple Sclerosis (cerebrospinal fluid)</term><term>Multiple Sclerosis (therapy)</term><term>Parkinson Disease (cerebrospinal fluid)</term><term>Parkinson Disease (therapy)</term><term>Serotonin (cerebrospinal fluid)</term><term>Serotonin (metabolism)</term><term>Thalamic Nuclei (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Dopamine</term><term>Enkephalin, Methionine</term><term>Serotonin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Serotonin</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Multiple Sclerosis</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Thalamic Nuclei</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Multiple Sclerosis</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Electric Stimulation Therapy</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High-frequency electrical stimulations of thalamic nuclei are currently used for the suppression of parkinsonian or essential tremor and for the relief of some types of intractable pain in man. However, the mechanisms by which such stimulations exert their therapeutic effects are essentially unknown. Attempts were made to provide some insight into these mechanisms by measuring the levels of the dopamine metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) and met-enkephalin-like immunoreactivity in ventricular cerebrospinal fluid (CSF) of patients with Parkinson's disease (PD) or multiple sclerosis (MS) after a 30-minute therapeutic electrical stimulation of the ventralis intermedius nucleus of the thalamus. In nonstimulated control patients, the levels of these compounds did not significantly differ in two CSF samples taken 30 minutes apart. In stimulated patients, a decrease in dopamine metabolite levels associated with a relative increase in met-enkephalin-like immunoreactivity were observed in the CSF sample taken after the 30-minute stimulation as compared to the sample taken immediately before the stimulation. In contrast, the levels of 5-HIAA remained unaffected by the stimulation. These data confirmed the existence of negative interactions between dopaminergic and enkephalinergic systems in man similar to those previously demonstrated in rats. In addition, they suggest that alterations in dopaminergic or enkephalinergic neurotransmission might be involved in the therapeutic action of thalamic electrical stimulation in patients with parkinsonian symptoms and other patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10442254</PMID><DateCreated><Year>1999</Year><Month>09</Month><Day>28</Day></DateCreated><DateCompleted><Year>1999</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>4</Issue><PubDate><MedlineDate>1999 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.</ArticleTitle><Pagination><MedlinePgn>231-8</MedlinePgn></Pagination><Abstract><AbstractText>High-frequency electrical stimulations of thalamic nuclei are currently used for the suppression of parkinsonian or essential tremor and for the relief of some types of intractable pain in man. However, the mechanisms by which such stimulations exert their therapeutic effects are essentially unknown. Attempts were made to provide some insight into these mechanisms by measuring the levels of the dopamine metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) and met-enkephalin-like immunoreactivity in ventricular cerebrospinal fluid (CSF) of patients with Parkinson's disease (PD) or multiple sclerosis (MS) after a 30-minute therapeutic electrical stimulation of the ventralis intermedius nucleus of the thalamus. In nonstimulated control patients, the levels of these compounds did not significantly differ in two CSF samples taken 30 minutes apart. In stimulated patients, a decrease in dopamine metabolite levels associated with a relative increase in met-enkephalin-like immunoreactivity were observed in the CSF sample taken after the 30-minute stimulation as compared to the sample taken immediately before the stimulation. In contrast, the levels of 5-HIAA remained unaffected by the stimulation. These data confirmed the existence of negative interactions between dopaminergic and enkephalinergic systems in man similar to those previously demonstrated in rats. In addition, they suggest that alterations in dopaminergic or enkephalinergic neurotransmission might be involved in the therapeutic action of thalamic electrical stimulation in patients with parkinsonian symptoms and other patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bourgoin</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM U.288, Faculty of Medicine Pitié-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostaing-Rigattieri</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Berberich</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Duvaldestin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fattaccini</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hamon</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cesselin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>58569-55-4</RegistryNumber><NameOfSubstance UI="D004744">Enkephalin, Methionine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004744" MajorTopicYN="N">Enkephalin, Methionine</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013787" MajorTopicYN="N">Thalamic Nuclei</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10442254</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10442254
|texte= Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10442254" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |